Long‐Term Recurrence‐Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR ‐Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report
Cancer Reports · 2026-11 · 9 (11)
DOI: 10.1002/cnr2.70729 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, online erschienen am 12.11.2026. Verfasst von Minlian Nong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinosarcoma. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Science and Technology Program, Self-funded Scientific Research Project of the Health Commission of Guangxi Zhuang Autonomous Region.
Abstract (Originalsprache)
Background
Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare subtype of non‐small cell lung cancer (NSCLC), which generally shows limited response to chemoradiotherapy and confers poor overall survival (OS). Recent progress in molecular targeted therapy has provided potential therapeutic strategies for this disease. Herein, we report a rare case of PSC harboring concurrent EGFR L858R and PIK3CA exon 10 mutations. The patient underwent radical surgical resection followed by adjuvant third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) targeted therapy, and sustained long‐term disease‐free survival (DFS) was observed during clinical follow‐up. Although this case showed a favorable outcome, causality cannot be established from a single case report. Whether adjuvant furmonertinib contributed to the long‐term DFS remains uncertain and requires further investigation. Case A middle‐aged female presented with cough, expectoration, and hemoptysis. Percutaneous lung biopsy confirmed Stage IIIA pulmonary sarcomatoid carcinoma, and radical surgical resection was subsequently performed. Postoperative next‐generation sequencing identified concomitant EGFR L858R and PIK3CA exon 10 mutations. The patient received adjuvant furmonertinib as postoperative targeted therapy. No tumor recurrence was detected throughout follow‐up, with a documented DFS of 48 months.
Conclusion
Surgical resection remains the primary treatment for patients with early‐stage PSC, and postoperative molecular testing is critical to identify targetable mutations. This patient obtained durable DFS after radical resection combined with adjuvant third‐generation EGFR‐TKI targeted therapy. Additional large‐scale studies are needed to confirm the efficacy of adjuvant EGFR‐TKIs in PSC patients with dual EGFR/PIK3CA mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
ORCID-Profile: Minlian Nong, Xiang Tan
Förderung
- Guangxi Science and Technology Program
- Self-funded Scientific Research Project of the Health Commission of Guangxi Zhuang Autonomous Region
Zitieren
APA
Nong, M., & Tan, X. (2026). Long‐Term Recurrence‐Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR ‐Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report. Cancer Reports, 9(11). https://doi.org/10.1002/cnr2.70729
Vancouver
Nong M, Tan X. Long‐Term Recurrence‐Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR ‐Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report. Cancer Reports. 2026;9(11). doi:10.1002/cnr2.70729
BibTeX
@article{Nong2026,
author = {Nong, Minlian and Tan, Xiang},
title = {Long‐Term Recurrence‐Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR ‐Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/cnr2.70729}
}
EUVIMED